- Home
- ARHS vs GERN Comparison
ARHS vs GERN Comparison
Compare ARHS & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARHS | GERN |
|---|---|---|
| Founded | 1986 | 1990 |
| Country | United States | United States |
| Employees | N/A | 258 |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 956.8M | 808.3M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | ARHS | GERN |
|---|---|---|
| Price | $7.73 | $1.44 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 3 |
| Target Price | ★ $10.78 | $2.17 |
| AVG Volume (30 Days) | 1.3M | ★ 13.6M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.78% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $1,379,222,000.00 | N/A |
| Revenue This Year | $7.23 | $26.91 |
| Revenue Next Year | $7.10 | $43.75 |
| P/E Ratio | $386.50 | ★ N/A |
| Revenue Growth | ★ 8.51 | N/A |
| 52 Week Low | $5.57 | $1.04 |
| 52 Week High | $12.97 | $2.01 |
Technical Indicators
Market Signals| Indicator | ARHS | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 52.18 | 55.50 |
| Support Level | $6.19 | $1.23 |
| Resistance Level | $8.61 | $1.46 |
| Average True Range (ATR) | 0.41 | 0.09 |
| MACD | -0.07 | 0.01 |
| Stochastic Oscillator | 43.93 | 44.42 |
Price Performance
Historical ComparisonAbout ARHS Arhaus Inc.
Arhaus Inc is a growing lifestyle brand and omnichannel retailer of premium home furniture. The company offers merchandise in several categories, including furniture, outdoor, lighting, textiles, and decor through its Retail and e-commerce sales channels.
About GERN Geron Corporation
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.